A randomized phase I/II study of ABT-888 in combination with temozolomide in recurrent temozolomide resistant glioblastoma: An NRG oncology RTOG group study

Journal of Neuro-Oncology

Volumn 126, Issue 2, 2016, Pages 309-316

  Robins, H Ian ^a   Zhang, Peixin ^b   Gilbert, Mark R ^c   Chakravarti, Arnab ^d   de Groot, John F ^e   Grimm, Sean A ^f   Wang, Fen ^g   Lieberman, Frank S ^h   Krauze, Andra ^c   Trotti, Andy M ⁱ   Mohile, Nimish ^j   Kee, Andrew Y J ^k   Colman, Howard ^l   Cavaliere, Robert ^d   Kesari, Santosh ^m   Chmura, Steven J ⁿ   Mehta, Minesh ^o  

^a UNIVERSITY OF WISCONSIN   (United States)

^b NRG ONCOLOGY STATISTICS AND DATA MANAGEMENT CENTER   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

^d THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f Candence Cancer Center   (United States)

^g UNIVERSITY OF KANSAS   (United States)

^h UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

ⁱ H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^j UNIVERSITY OF ROCHESTER   (United States)

^k Legacy Health   (United States)

^l UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^m UNIVERSITY OF CALIFORNIA   (United States)

ⁿ UNIVERSITY OF CHICAGO   (United States)

^o UNIVERSITY OF MARYLAND MEDICAL SYSTEM   (United States)

more..

Author keywords

ABT 888; Glioblastoma; Temozolomide; Velparib

Indexed keywords

BEVACIZUMAB; TEMOZOLOMIDE; VELIPARIB; ALKYLATING AGENT; BENZIMIDAZOLE DERIVATIVE; DACARBAZINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; BREAST DISEASE; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; EAR DISEASE; ENDOCRINE DISEASE; EYE DISEASE; FEMALE; GASTROINTESTINAL DISEASE; GENITAL SYSTEM DISEASE; GLIOBLASTOMA; HEART DISEASE; HEMATOLOGIC DISEASE; HUMAN; IMMUNOPATHOLOGY; INCIDENCE; INFECTION; INFESTATION; INJURY; INNER EAR DISEASE; INTOXICATION; KIDNEY DISEASE; LYMPHATIC SYSTEM DISEASE; LYMPHOCYTE COUNT; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MEDIASTINUM DISEASE; MENTAL DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NEOPLASM; NEUROLOGIC DISEASE; NEUTROPENIA; NEUTROPHIL COUNT; NUTRITIONAL DISORDER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SIDE EFFECT; SKIN DISEASE; SURVIVAL TIME; THORAX DISEASE; THROMBOCYTE COUNT; THROMBOCYTOPENIA; URINARY TRACT DISEASE; VASCULAR DISEASE; ANALOGS AND DERIVATIVES; BRAIN NEOPLASMS; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DISEASE FREE SURVIVAL; DRUG EFFECTS; DRUG RESISTANCE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, ALKYLATING; BENZIMIDAZOLES; BEVACIZUMAB; BRAIN NEOPLASMS; DACARBAZINE; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY, COMBINATION; FEMALE; GLIOBLASTOMA; HUMANS; MALE; MIDDLE AGED; POLY(ADP-RIBOSE) POLYMERASE INHIBITORS; SURVIVAL ANALYSIS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84945272125     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-015-1966-z     Document Type: Article

References (19)

1. Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996. doi:10.1056/NEJMoa043330
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M, Lacombe D, Cairncross JG, Mirimanoff RO (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466. doi:10.1016/S1470-2045(09)70025-7
3. Stupp R, Wong E, Scott C, Taillibert S, Kanner A, Kesari S, Ram Z (2014) Interim analysis of the EF-14 trial: a prospective, multicenter trial of NovoTTF-100A together with temozolomide compared to temozolomide alone in patients with newly diagnosed GBM. Neuro-Oncology 16:v167-v167. doi:10.1093/neuonc/nou265.40 (abstr NT-140)
4. Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G et al (1995) Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 345:1008-1012
5. Magnuson W, Ian Robins H, Mohindra P, Howard S (2014) Large volume reirradiation as salvage therapy for glioblastoma after progression on bevacizumab. J Neurooncol 117:133-139. doi:10.1007/s11060-014-1363-z
6. Hegi ME, Diserens AC, Gorlia T, Hamou MF, de Tribolet N, Weller M, Kros JM, Hainfellner JA, Mason W, Mariani L, Bromberg JE, Hau P, Mirimanoff RO, Cairncross JG, Janzer RC, Stupp R (2005) MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352:997-1003. doi:10.1056/NEJMoa043331
7. Tolcher AW, Gerson SL, Denis L, Geyer C, Hammond LA, Patnaik A, Goetz AD, Schwartz G, Edwards T, Reyderman L, Statkevich P, Cutler DL, Rowinsky EK (2003) Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer 88:1004-1011. doi:10.1038/sj.bjc.6600827
8. Tentori L, Graziani G (2005) Chemopotentiation by PARP inhibitors in cancer therapy. Pharmacol Res 52:25-33. doi:10.1016/j.phrs.2005.02.010
9. Tentori L, Orlando L, Lacal PM, Benincasa E, Faraoni I, Bonmassar E, D’Atri S, Graziani G (1997) Inhibition of O6-alkylguanine DNA-alkyltransferase or poly(ADP-ribose) polymerase increases susceptibility of leukemic cells to apoptosis induced by temozolomide. Mol Pharmacol 52:249-258
10. Wedge SR, Porteous JK, Newlands ES (1996) 3-aminobenzamide and/or O6-benzylguanine evaluated as an adjuvant to temozolomide or BCNU treatment in cell lines of variable mismatch repair status and O6-alkylguanine-DNA alkyltransferase activity. Br J Cancer 74:1030-1036
11. Lepeak LM, Leal T, Robins HI (2010) Preclinical and clinical development of Velaparib (ABT-888): a poly (ADP-ribose) polymerase inhibitor. Drugs Futur 35:815-822
12. Kummar S, Kinders R, Gutierrez ME, Rubinstein L, Parchment RE, Phillips LR, Ji J, Monks A, Low JA, Chen A, Murgo AJ, Collins J, Steinberg SM, Eliopoulos H, Giranda VL, Gordon G, Helman L, Wiltrout R, Tomaszewski JE, Doroshow JH (2009) Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. J Clin Oncol 27:2705-2711. doi:10.1200/JCO.2008.19.7681
13. Robins HI, Wang M, Gilbert MR, Chakravarti A, Grimm S, Penas-Prado M, Chaudhary R, Anderson PJ, Elinzano H, Gilbert RA, Mehta M (2012) Phase I results from RTOG 0929, a randomized phase I/II study of ABT-888 (veliparib) in combination with temozolomide (TMZ) in recurrent, TMZ-resistant glioblastoma. Neuro Oncol 14:vi65 (abstr NO-14)
14. Wong ET, Hess KR, Gleason MJ, Jaeckle KA, Kyritsis AP, Prados MD, Levin VA, Yung WK (1999) Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol 17:2572-2578
15. Simon R (1989) Optimal two-stage designs for phase II clinical trials. Control Clin Trials 10:1-10
16. Lassman AB, Iwamoto FM, Gutin PH et al (2008) Patterns of relapse and prognosis after bevacizumab (BEV) failure in recurrent glioblastoma (GBM). J Clin Oncol 26:2028 (96S abstr 2028)
17. Wick W, Weller M, van den Bent M, Sanson M, Weiler M, von Deimling A, Plass C, Hegi M, Platten M, Reifenberger G (2014) MGMT testing-the challenges for biomarker-based glioma treatment. Nat Rev Neurol 10:372-385. doi:10.1038/nrneurol.2014.100
18. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733-4740. doi:10.1200/JCO.2008.19.8721
19. Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol 27:740-745. doi:10.1200/JCO.2008.16.3055